CONCLUSIONS: Based on the proposed model, it is possible to accurately estimate the risk of positive BS at kidney cancer staging using pre-operative characteristics. If BS is performed only when the risk of positive result is >5%, a negative BS is spared in 80% of the population and a positive BS is missed in 2% of the population only. When compared to decision-making based on symptoms only, which represents the strategy recommended by available guidelines, the proposed model resulted more objective, statistically more accurate and clinically associated with higher net benefit. These figures support an update of the available guidelines.
INTRODUCTION AND OBJECTIVES: Oncologic surveillance is an integral part of renal cell carcinoma (RCC) care. Whether this practice affords a survival benefit remains unclear. Our objective was to determine whether detection of RCC recurrences in an asymptomatic vs. symptomatic manner influenced all cause mortality following kidney cancer surgery.
METHODS: We identified 737 patients who underwent partial or radical nephrectomy for non-metastatic RCC at our institution between 1998 and 2016. Overall survival in patients with recurrence stratified by the type of detection (asymptomatic vs symptomatic) was estimated using Kaplan-Meier probabilities and compared with the log rank test. Cox proportional hazard regression models were used to evaluate the impact of the type of recurrence detection on survival.
RESULTS: A total of 78 patients (10.6%) experienced recurrence after surgery at a median interval of 17 months (range, 0 -172). Median postoperative follow-up for all recurrences was 47 months (range, 3 -230). Recurrences were detected in 63 (80.8%) patients using routine surveillance (asymptomatic) and in 15 (19.2%) patients due to symptoms. There were no significant differences in clinicopathological features of the primary tumors between the two types of detection. Five and 10-year overall survival among patients with asymptomatic vs. symptomatic recurrences was 56% and 37% vs. 24% and 8%, respectively (p ¼ 0.0003) ( Figure) . On multivariable analysis, patients in whom recurrences were detected from symptoms showed a 3-fold increased risk of death as compared to those in whom recurrences were detected asymptomatically via routine surveillance (HR 3.15, 95% CI 1.33, 7.46; p ¼ 0.009).
CONCLUSIONS: Capturing RCC recurrences in an asymptomatic manner during routine surveillance is associated with improved patient survival. Further investigation to optimize a surveillance protocol which balances the benefit of early detection with the cost of follow-up is needed.
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PD52-07 MEDICATION USE AND KIDNEY CANCER RISK: A POPULATION-BASED STUDY
Madhur Nayan*, David Juurlink, Peter Austin, Erin Macdonald, Antonio Finelli, Girish Kulkarni, Robert Hamilton, Toronto, Canada INTRODUCTION AND OBJECTIVES: Exposure to commonlyprescribed medications may be associated with cancer risk. However, there is limited data in kidney cancer. Furthermore, methods of classifying cumulative medication exposure in previous studies may be prone to bias.
METHODS: We conducted a population-based case-control study utilizing health care databases in Ontario, Canada. Individuals enrolled as cases were aged 66 with an incident diagnosis of kidney cancer. For each individual enrolled as a case, we identified up to four individuals without kidney cancer as controls matched on age, sex, history of hypertension, comorbidity score, and geographic location. Cumulative exposure to commonly prescribed medications hypothesized to modulate cancer risk were obtained using prescription claims data. We modelled exposure in four different fashions: 1) as continuous exposures using a) fractional polynomials (which allow for non-linear relationship between a continuous exposure and outcome) or b) a linear relationship; and 2) as dichotomous exposures denoting a) 3 years or greater vs. less than 3 years of cumulative exposure; or b) 0 ever 0 vs. 0 never 0 exposure. We used conditional logistic regression to estimate the association of medication exposure on incident kidney cancer.
RESULTS: We identified 10,377 incident cases of kidney cancer and 35,939 matched controls. When utilizing fractional polynomials, increasing cumulative exposure to aspirin, selective serotonin reuptake inhibitors, and proton-pump inhibitors were associated with significantly reduced risk of developing kidney cancer, while increasing exposure to anti-hypertensive drugs was associated with significantly increased risk (Table 1 ). The directions of association were relatively consistent across analyses; however, the magnitudes were sensitive to the method of analysis (Table 2) .
CONCLUSIONS: Our study provides impetus to further explore the effect of commonly-prescribed medications on carcinogenesis to identify modifiable pharmacological interventions to reduce the risk of kidney cancer. INTRODUCTION AND OBJECTIVES: Cystic renal cell carcinomas (RCC) are suggested to be clinically indolent. As such, a distinct pathologic staging category for these lesions was recently proposed. While not without merit, these recommendations fail to account for limitations in the ability of modern imaging to differentiate cystic RCC from more biologically aggressive mimics. We evaluated the frequency of high grade kidney cancer in the highly selected cohort of surgically resected renal masses having cystic appearance on pre-operative radiographic imaging.
METHODS: A prospectively maintained institutional database was queried for clinically cystic renal masses that underwent surgery from January 2000 -June 2016 (n¼2,729 kidney surgeries). Patient and tumor characteristics including age at surgery, smoking history, Charlson comorbidity index (CCI), gender, race, BMI, surgery date, laterality, Bosniak classification, histology, grade, size, and nearness to the collecting system were tabulated. Associations between tumor grade and patient/tumor characteristics were evaluated using generalized estimating equations.
RESULTS: Eighty-nine patients (n¼101 cystic lesions) met strict inclusion criteria; the majority (77%) were older than 50 years of age and the mean Charlson comorbidity index was 1.15 (SD1.48) ( Table 1) . Of the 101 clinically cystic renal masses, 23% were confirmed pathologically as high grade RCC while 77% were low grade RCC (n¼56) or benign (n¼22). CCI was associated with high grade surgical pathology (OR 1.37, 95% CI 1.05-1.79, p ¼ 0.02). There was no association between tumor grade and the remainder of the patient/ tumor characteristics analyzed.
CONCLUSIONS: Recently proposed changes to the kidney cancer staging system define a tumor's cystic nature based on pathologic examination. Proceeding with surgery for a radiographically "cystic" renal mass was a rare event in our cohort; however, among those that went onto surgery, nearly a quarter harbored high grade pathology. Before making changes to the clinical RCC staging system, a better understanding of the limitations inherent to radiographic determination of low malignant potential, cystic renal masses is necessary.
Source of Funding: None
PD52-09 THROMBOEMBOLIC EVENTS DURING TREATMENT FOR RENAL CELL CARCINOMA: MUST WE PREVENT?
Jamie Olsen*, Steven Jubelirer, Charleston, WV; Samuel Umstot, Morgantown, WV; Samuel Deem, Charleston, WV INTRODUCTION AND OBJECTIVES: Renal mass detection has been on a steady incline over the past decade and subsequently, surgery for solid renal masses has also increased. 900,000 Americans are diagnosed with a VTE each year with the average cost being $56,000 to treat each incident. VTE is the number two cause of death behind the primary malignancy itself. As quality indicators and outcomes are more frequently being linked with reimbursement, venous thromboembolism (VTE) prevention has gained increased attention. Increasing the number of surgeries will also increase the incidence of VTE. The purpose of this study is to identify the incidence of VTE among renal cell carcinoma patients that have undergone definitive surgical therapy and to see if pharmacological prophylaxis following surgery is warranted.
METHODS: Over a fourteen year period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , all patients who had surgery for renal cell carcinoma were examined. A total of 900 patients had either open, laparoscopic or robotic surgery. This included partial, radical and cytoreductive nephrectomies. All VTE e992 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
